# US 2001/0027185 A1 · Methods and compositions for treating inflammatory response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027185 A1
- Document ID: US20010027185A1
- Status: Published application
- Kind: A1
- Application number: 09/827,083
- Filed: 2001-04-05
- Published: 2001-10-04
- Earliest claimed: 1999-02-01
- Assignees: University of Virginia Patent Foundation
- Inventors: Joel M. Linden; Gail W. Sullivan; Ian J. Sarembock; Timothy MacDonald; Mark Okusa; Irving L. Kron; W. Michael Scheld
- Web page: https://patentgrep.com/patent/US20010027185A1

## CPC

- C07H 19/06: Pyrimidine radicals
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Compounds and methods are provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.

## Claims

### Claim 1

A compound of the formula (I): 7
wherein (a) each R is individually hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or phenyl(C1-C3)-alkyl;
(b) X is —CH2OH, —CO2R2, -OC(O)R2 or C(O)NR3R4;
(c) each of R2, R3 and R4 is individually H, C1-6-alkyl; C1-6-alkyl substituted with 1-3 C1-6-alkoxy, C3-C7 cycloalkyl, C1-6-alkylthio, halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino, or C6-10-aryl, wherein aryl may be substituted with 1-3 halogen, C1-6-alkyl, hydroxy, amino, mono(C1-6-alkyl)amino, or di(C1-6-alkyl)amino; C6-10-aryl; or C6-10-aryl substituted with 1-3 halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino or C1-6-alkyl;
(d) R1 is (X-(Z)-)n[(C3-C10)cycloalkyl]-(Z′)- wherein Z and Z′ are individually (C1-C6)alkyl, optionally interrupted by 1-3 S or noperoxide O, or is absent, and n is 1-3; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1 wherein X is —CH2OH or —C(O)NR3R4.

### Claim 3 (depends on 2)

A compound of claim 2 wherein R3 is H and R4 is (C1-C4)alkyl.

### Claim 4 (depends on 1)

A compound of claim 1 wherein each R is H or (C1-C4)alkyl.

### Claim 5 (depends on 1)

A compound of claim 1 wherein Z′ is —CH2— or —CH2—CH2—.

### Claim 6 (depends on 5)

A compound of claim 5 wherein Z is —CH2— or —CH2—CH2—.

### Claim 7 (depends on 1)

A compound of claim 1 wherein R′ comprises cyclohexyl or cyclopentyl.

### Claim 8 (depends on 7)

A compound of claim 7 wherein X is (C1-C4)alkoxycarbonyl, C(O)NR3R4 or acetoxymethyl.

### Claim 9 (depends on 7)

A compound of claim 7 wherein X is carboxy.

### Claim 10 (depends on 7)

A compound of claim 7 wherein X—Z and Z′ are trans.

### Claim 11 (depends on 1)

A compound of claim 1 wherein R is H, X is ethylaminocarbonyl, and R′ is 2(4-methoxycarbonyl-cyclohexylmethyl)ethynyl or 2-(4-carboxy-cyclohexylmethyl)ethynyl.

### Claim 12 (depends on 1)

A compound of claim 1 wherein R is H, X is ethylaminocarbonyl, and R2 is 2-(4-acetoxymethyl-cyclohexylmethyl)ethynyl.

### Claim 13

Methyl-4-(3-{9-[(4S,5S,2R, 3R)-5-(N-ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-6-aminopurin-2-yl)}prop-2-ynyl)cyclohexane-carboxylate.

### Claim 14

A therapeutic method to inhibit an inflammatory response comprising administering to a mammal in need of said therapy, an effective anti-inflammatory amount of a compound of formula (I): 8
wherein (a) each R is individually hydrogen, C1-C6 alkyl C3-C7 cycloalkyl, phenyl or phenyl(C1-C3)-alkyl;
(b) X is —CH2OH, —CO2R2, —OC(O)R2 or C(O)NR3R4;
(c) each of R2, R3 and R4 is individually H, C1-6-alkyl; C1-6-alkyl substituted with 1-3 C1-6-alkoxy, C3-C7-cycloalkyl, C1-6-alkylthio, halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino, or C6-10 -aryl, wherein aryl may be substituted with 1-3 halogen, C1-6-alkyl, hydroxy, amino, mono(C1-6-alkyl)amino, or di(C1-6-alkyl)amino; C6-10-aryl; or C6-10-aryl substituted with 1-3 halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino or C1-6-alkyl;
(d) each of R3 and R4 is individually hydrogen, C3-7-cycloalkyl, or any of the meanings of R2; and
(e) R1is (X-(Z)-)n[(C3-Cl10)cycloalkyl]-(Z′)- wherein Z and Z′ are individually (C1-C6)alkyl, optionally interrupted by 1-3 S or noperoxide O, or is absent, and n is 1-3; or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method of claim 14 wherein X is —CH2OH or —C(O)NR3R4.

### Claim 16 (depends on 15)

The method of claim 15 wherein R3 is H and R4 is (C1-C4)alkyl.

### Claim 17 (depends on 14)

The method of claim 14 wherein each R is H or (C1-C4)alkyl.

### Claim 18 (depends on 14)

The method of claim 14 wherein Z′ is —CH2— or —CH2-CH2—.

### Claim 19 (depends on 17)

The method of claim 17 wherein Z is —CH2— or —CH2-CH2—.

### Claim 20 (depends on 14)

The method of claim 14 wherein R′ comprises cyclohexyl or cyclopentyl.

### Claim 21 (depends on 20)

The method of claim 20 wherein X is (C1-C4)alkoxycarbonyl or acetoxymethyl.

### Claim 22 (depends on 20)

The method of claim 20 wherein X is carboxy.

### Claim 23 (depends on 20)

The method of claim 20 wherein X—Z and Z′ are trans.

### Claim 24 (depends on 14)

A method of claim 14 wherein R is H, X is ethylaminocarbonyl and R′ is 2-(4-methoxycarbonyl-cyclohexyhnethyl)ethynyl or 2-(4-carbony-cyclohexylmethyl)ethynyl.

### Claim 25 (depends on 14)

A method of claim 14 wherein R is H, X is ethylaminocarbonyl, and R2 is 2-(4-acetoxymethyl-cyclohexylmethyl)ethynyl.

### Claim 26 (depends on 14)

The method of claim 14 further comprising administering a Type IV phosphodiesterase inhibitor in combination with the compound of formula (I).

### Claim 27 (depends on 14)

The method of claim 14 wherein rolipram is administered in combination with said compound of formula (I).

### Claim 28 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to ischemia.

### Claim 29 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to atherosclerosis.

### Claim 30 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to an autoimmune disease.

### Claim 31 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to ischemia/reperfusion injury.

### Claim 32 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to stroke, traumatic brain injury, or spinal cord injury.

### Claim 33 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to organ, tissue or cell transplantation.

### Claim 34 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to infection.

### Claim 35 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to a skin disease.

### Claim 36 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to angioplasty, stent placement, shunt placement or grafting.

### Claim 37 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to an allergic disease.

### Claim 38 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to a wasting disease.

### Claim 39 (depends on 14)

The method of claim 14 wherein the inflammatory response is due to immunosuppressive therapy.

### Claim 40 (depends on 1)

A therapeutic composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

### Claim 41 (depends on 37)

The composition of claim 37 further comprising a Type IV phosphodiesterase inhibitor.

### Claim 42 (depends on 38)

The composition of claim 38 wherein the inhibitor is rolipram.

### Claim 43 (depends on 38)

The composition of claim 38 wherein the carrier is a liquid carrier.

### Claim 44 (depends on 43)

The composition of claim 43 which is adapted for parenteral administration.
